Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASGR1 | P07306 | 5/20 | 0.41 |
| ▸ | SLC5A2 | P31639 | 12/20 | 0.38 |
| ▸ | SLC5A1 | P13866 | 9/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11296106 | 1.00 | ASGR1 (0.41) | ASGR1SLC5A2SLC5A1 | |
| SCHEMBL15216212 | 1.00 | ASGR1 (0.41) | ASGR1SLC5A2SLC5A1 | |
| SCHEMBL24849981 | 0.74 | SLC5A2 (0.36) | ASGR1SLC5A2SLC5A1 | |
| SCHEMBL22876212 | 0.72 | — | — | |
| SCHEMBL20997484 | 0.68 | SLC5A2 (0.36) | ASGR1SLC5A2SLC5A1 | |
| SCHEMBL22459100 | 0.68 | SLC5A2 (0.36) | ASGR1SLC5A2SLC5A1 | |
| SCHEMBL19510142 | 0.68 | SLC5A2 (0.36) | ASGR1SLC5A2SLC5A1 | |
| SCHEMBL19510143 | 0.68 | SLC5A2 (0.36) | ASGR1SLC5A2SLC5A1 | |
| SCHEMBL16750224 | 0.61 | GAA (0.35) | — | |
| SCHEMBL24256008 | 0.60 | ASGR1 (0.45) | ASGR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170304262-A1 | SGLT-2 INHIBITORS FOR TREATING METABOLIC DISORDERS IN PATIENTS WITH RENAL IMPAIRMENT OR CHRONIC KIDNEY DISEASE | MERCK SHARP & DOHME LLC | 2017-10-26 | — | — | US | disclosed |
| US-20170304262-A1 | SGLT-2 INHIBITORS FOR TREATING METABOLIC DISORDERS IN PATIENTS WITH RENAL IMPAIRMENT OR CHRONIC KIDNEY DISEASE | MERCK SHARP & DOHME LLC | 2017-10-26 | — | — | US | disclosed |
| US-9439902-B2 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives | PFIZER INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9308204-B2 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives | PFIZER INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-20150065565-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER INC. (US) | 2015-03-05 | — | — | US | disclosed |
| US-20150065513-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER INC. (US) | 2015-03-05 | — | — | US | disclosed |
| US-8669380-B2 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives | PFIZER INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-20130225487-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20120184486-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER INC. | 2012-07-19 | — | — | US | disclosed |
| US-8080580-B2 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives | PFIZER INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-8080580-B2 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives | PFIZER INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-20100056618-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER INC | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056618-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | SLC5A2, SLC5A1, SLC2A2 | ASGR1 1479/4885SLC5A2 1/4885SLC5A1 2/4885 |
| US-20120184486-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | SLC5A2, SLC5A1, SLC2A2 | ASGR1 1507/4885SLC5A2 1/4885SLC5A1 2/4885 |
| US-20150065565-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | SLC5A2, SLC5A1, SLC2A2 | ASGR1 1507/4885SLC5A2 1/4885SLC5A1 2/4885 |
| US-20130225487-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | SLC5A2, SLC5A1, SLC2A2 | ASGR1 1507/4885SLC5A2 1/4885SLC5A1 2/4885 |
| US-20170304262-A1 | SGLT-2 INHIBITORS FOR TREATING METABOLIC DISORDERS IN PATIENTS WITH RENAL IMPAIRMENT OR CHRONIC KIDNEY DISEASE | SLC5A1, SLC5A2, SLC2A1 | ASGR1 826/4885SLC5A2 2/4885SLC5A1 1/4885 |
| US-20150065513-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | SLC5A2, SLC5A1, SLC2A2 | ASGR1 1507/4885SLC5A2 1/4885SLC5A1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.